NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

356. Zhou Q, Yin W, Du Y, Lu J. For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures. PLoS One 2014;9:e83646. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24392090 . 357. Tolaney S, Barry W, Dang C, et al. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2- positive breast cancer (BC) [abstract]. San Antonio Breast Symposium Meeting Abstract 2013:Abstract S 1-04 (Oral Presentation). Available at: 358. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27:5693-5699. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19884553 . 359. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol 2007;25(Suppl 18):Abstract 512. Available at: http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/512 . 360. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:1090-1096. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18296421 . 361. von MG, Baselga J, Bradbury I, et al. Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4– 11/BO25126/TOC4939g) [abstract]. Cancer Res 2011; 71(Suppl 24 ):Abstract OT1-02-04.: 362. A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer (Clinical Trial ID: NCT01358877). Available at: http://clinicaltrials.gov/ct2/show/NCT01358877 .

363. Aukema TS, Straver ME, Peeters MJ, et al. Detection of extra- axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer 2010;46:3205-3210. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20719497 . 364. Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746-4751. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18695254 . 365. Groheux D, Moretti JL, Baillet G, et al. Effect of ( 18 )F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008;71:695-704. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18436392 . 366. van der Hoeven JJM, Krak NC, Hoekstra OS, et al. 18 F-2-fluoro-2- deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22:1253-1259. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15051773 . 367. Niikura N, Costelloe CM, Madewell JE, et al. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist 2011;16:1111-1119. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21765193 . 368. Morris PG, Lynch C, Feeney JN, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010;28:3154-3159. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20516453 . 369. Alessio AM, Kinahan PE, Cheng PM, et al. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am 2004;42:1017-1032. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15488555 .

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-93